We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
General description of the gene and the encoded protein(s) using information from HGNC and Ensembl, as well as predictions made by the Human Protein Atlas project.
Gene namei
Official gene symbol, which is typically a short form of the gene name, according to HGNC.
All transcripts of all genes have been analyzed regarding the location(s) of corresponding protein based on prediction methods for signal peptides and transmembrane regions.
Genes with at least one transcript predicted to encode a secreted protein, according to prediction methods or to UniProt location data, have been further annotated and classified with the aim to determine if the corresponding protein(s) are secreted or actually retained in intracellular locations or membrane-attached.
Remaining genes, with no transcript predicted to encode a secreted protein, will be assigned the prediction-based location(s).
The annotated location overrules the predicted location, so that a gene encoding a predicted secreted protein that has been annotated as intracellular will have intracellular as the final location.
Membrane, Intracellular
HUMAN PROTEIN ATLAS INFORMATION
Upregulated in disease (PEA)i
A gene is classified as upregulated in a disease if the average concentration of all samples of that disease is significantly higher (adj P-value<0.005 and NPX difference>=1) than the average concentration of samples of all diseases as measured by PEA . For gender specific diseases the analysis includes only samples corresponding to the same gender from the other diseases.
No
Blood-based immunoassayi
The blood-based immunoassay category applies to actively secreted proteins and is based on plasma or serum protein concentrations established with enzyme-linked immunosorbent assays, compiled from a literature search. The categories include: detected and not detected, where detection refers to a concentration found in the literature search.
Not analysed since only proteins predicted to be actively secreted to blood is analysed here
Mass spectrometryi
Detection or not of the gene in blood, based on spectral count estimations from a publicly available mass spectrometry-based plasma proteomics data set obtained from the PeptideAtlas.
Not detected
Proximity extension assayi
Detectibility in blood, based on proximity extension assays (Olink) for a longitudinal wellness study covering 76 individuals with six visits during two years.
Blood protein levels across 59 diseases and healthy individuals, profiled using the proximity extension assay (PEA) with the Olink Explore 1536.
PAN-CANCER EXTENDED BLOOD PROTEIN PROFILESi
Blood protein levels across five cancer types, profiled using the proximity extension assay (PEA) with the Olink Explore HT.
THE EFFECT OF AGE, BMI AND SEX ON BLOOD PROTEIN LEVELSi
Blood protein levels by age, BMI, and sex, measured using the proximity extension assay (PEA) with the Olink Explore 1536. In the age and sex scatterplots, samples are colored by disease class, and details for each data point can be viewed by hovering.
LONGITUDINAL ANALYSIS OF BLOOD PROTEIN LEVELS AT AGES 4, 8, 16 AND 24i
Longitudinal blood protein levels in healthy individuals measured at ages 4, 8, 16, and 24 years, shown separately for males and females. Relative protein abundances were quantified using the proximity extension assay (PEA) with the Olink Explore HT.
Age
LONGITUDINAL ANALYSIS OF BLOOD PROTEIN LEVELS DURING TWO YEARS AT OVER 50 YEAR IN AGEi
Blood protein levels in 96 healthy adults (aged 50–65) measured at six visits over a two-year period, shown separately for males and females. Relative protein abundances were quantified using the proximity extension assay (PEA) with the Olink Explore HT.
The Human Protein Atlas project is funded
